Company news
Serina Therapeutics, Inc. (AMEX:SER) news
Every Serina Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
April 7, 2026
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
April 2, 2026
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 25, 2026
Serina Therapeutics to Present at the 38th Annual Roth Conference
March 24, 2026
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Di...
March 18, 2026
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
February 24, 2026
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
February 19, 2026
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
January 28, 2026
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
January 15, 2026
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
December 11, 2025
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
December 10, 2025
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 13, 2025
Serina Therapeutics Provides Regulatory Update on SER-252 Program
November 3, 2025
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
October 8, 2025
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
October 6, 2025
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
September 9, 2025
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 8, 2025
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2...
August 25, 2025
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 11, 2025
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
July 29, 2025
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
July 28, 2025
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
July 10, 2025
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
July 1, 2025
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
June 23, 2025
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership wi...
June 17, 2025
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
June 17, 2025
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
May 22, 2025
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
May 14, 2025
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 8, 2025
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
April 29, 2025